Allahabad HC Puts On Hold UP’s Order To Suspend Sanjay Gandhi Hospital’s Licence

Lucknow/Amethi: The Lucknow bench of Allahabad High Court on Wednesday stayed the Uttar Pradesh government’s order suspending the licence of Sanjay Gandhi Hospital in Amethi.

A division bench of Justices Vivek Chaudhary and Manish Kumar said that inquiry against the hospital would go on. The bench also asked the state government to file its counter affidavit.

The bench was hearing a petition filed by the Sanjay Gandhi Hospital administration against the government’s order.

On September 18, the health department suspended the licence of Sanjay Gandhi Hospital in Munshiganj area of Amethi and halted OPD and emergency services, days after the death of a woman patient following an operation.

The hospital is run by Sanjay Gandhi Memorial Trust (SGMT) headed by Congress leader Sonia Gandhi.

Manoj Muttu, administrator of the trust, told PTI that a copy of the court’s order will be submitted to the chief medical officer of Amethi and as per the CMO’s directions functioning of the hospital will resume.

However, Muttu said he would like the hospital to resume functioning from Thursday.

On September 27, over 400 employees of the hospital sat on a dharna against the suspension of its licence. Local Congress leaders also staged a protest outside the CMO’s office.

The woman patient, Divya (22) who was admitted to the Sanjay Gandhi Hospital on September 14, went into a coma during a surgery. Her family members alleged that she was kept at the hospital for more than 30 hours before being referred to Lucknow where she died on September 16.

The next day, an FIR of causing death by negligence was registered against four employees of the hospital, including its chief executive officer.

Related Posts

  • Pharma
  • June 24, 2025
  • 59 views
India’s herbal and ayurvedic OTC market set to outpace global growth

New Delhi: India’s herbal and ayurvedic OTC (over the counter) market is expected to grow at a CAGR of 6.5 per cent, from $69 million in 2025 to $118 million…

  • Pharma
  • June 23, 2025
  • 128 views
Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

LONDON:  Ananda Pharma PLC (AQSE:ANA, OTCQB: ANANF) has manufactured 40 liters of its lead investigational product MRX1 and 40 liters of matched placebo in compliance with pharmaceutical Good Manufacturing Practices…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s herbal and ayurvedic OTC market set to outpace global growth

India’s herbal and ayurvedic OTC market set to outpace global growth

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ananda Pharma completes GMP manufacturing of MRX1 for clinical trials

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Ray of hope for HIV patients, as Hyderabad-based pharma giants secure nod for game-changing HIV drug

Drug licences of 9 pharma dealers suspended in Jammu

Drug licences of 9 pharma dealers suspended in Jammu